TY - JOUR T1 - Early prediction of preeclampsia in pregnancy with circulating cell-free RNA JF - medRxiv DO - 10.1101/2021.03.11.21253393 SP - 2021.03.11.21253393 AU - Mira N. Moufarrej AU - Sevahn K. Vorperian AU - Ronald J. Wong AU - Ana A. Campos AU - Cecele C. Quaintance AU - Rene V. Sit AU - Michelle Tan AU - Angela M. Detweiler AU - Honey Mekonen AU - Norma F. Neff AU - Maurice L. Druzin AU - Virginia D. Winn AU - Gary M. Shaw AU - David K. Stevenson AU - Stephen R. Quake Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/11/06/2021.03.11.21253393.abstract N2 - Liquid biopsies that measure circulating cell-free RNA (cfRNA) offer an unprecedented opportunity to noninvasively study the development of pregnancy-related complications and to bridge gaps in clinical care. Here, we used 404 blood samples from 199 pregnant mothers to identify and validate cfRNA transcriptomic changes that are associated with preeclampsia (PE), a multi-organ syndrome which is the second largest cause of maternal death globally. We find that changes in cfRNA gene expression between normotensive (NT) and preeclamptic mothers are striking and stable early in gestation, well before the onset of symptoms. These changes are enriched for genes specific to neuromuscular, endothelial, and immune cell types and tissues that reflect important aspects of PE physiology and suggest new hypotheses for disease progression. This enabled identification and independent validation of a panel of 18 genes whose measurement between 5–16 weeks of gestation can form the basis of a liquid biopsy test that would identify mothers at risk of PE well before the clinical symptoms manifest themselves. Finally, we demonstrate that cfRNA changes reflect the multifactorial nature of PE and provide a means to non-invasively monitor maternal organ health. Tests based on these observations could help predict and manage who is at risk for PE, an important and until now unachieved objective for obstetric care.Competing Interest StatementThe authors declare the following competing interests: M.N.M., S.K.V., G.M.S., D.K.S., and S.R.Q. are inventors on a patent application submitted by the Chan Zuckerberg Biohub and Stanford University that covers noninvasive early prediction of preeclampsia and monitoring maternal organ health over pregnancy. S.R.Q. is a founder, consultant, and shareholder of Mirvie. M.N.M. is also a shareholder of Mirvie.Funding StatementThis work was supported by the Chan Zuckerberg Biohub and the March of Dimes Foundation. M.N.M. is supported by the Stanford Bio-X Bowes Fellowship. S.K.V. is supported by a NSF Graduate Research Fellowship (Grant # DGE 1656518), the Benchmark Stanford Graduate Fellowship, and the Stanford ChEM-H Chemistry Biology Interface (CBI) training program. V.D.W. is supported by the H&H Evergreen Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewied and approved by the Institutional Review Board at Stanford University (#21956).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw and processed sequencing data will be deposited with the SRA and GEO, respectively. ER -